Baseline risk stratification or duration of prior therapy predicts prognosis in patients with metastatic renal cell carcinoma treated with axitinib

被引：3

作者：

Mizuno, Ryuichi ^{[1
]}

Mikami, Shuji ^{[2
]}

Takamatsu, Kimiharu ^{[1
]}

Shinojima, Toshiaki ^{[1
]}

Kikuchi, Eiji ^{[1
]}

Oya, Mototsugu ^{[1
]}

机构：

[1] Keio Univ, Sch Med, Dept Urol, Tokyo, Japan

[2] Keio Univ Hosp, Div Diagnost Pathol, Tokyo, Japan

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 47卷 / 12期

关键词：

renal cell carcinoma; metastasis; molecular targeted therapy; outcome; axitinib; CLINICAL BENEFIT; HYPERTENSION; SUNITINIB; EFFICACY; SORAFENIB; TRIAL; BEVACIZUMAB; EVEROLIMUS; BIOMARKER; AXIS;

D O I：

10.1093/jjco/hyx134

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: To elucidate the clinical prognostic factors in patients with metastatic renal cell carcinoma ( mRCC) treated with axitinib. Methods: A total of 58 patients were retrospectively analyzed. All patients received axitinib treatment for mRCC at Keio University hospital in Japan. Baseline clinical factors and on treatment adverse events were assessed to predict survival. Results: The median progression free survival ( PFS) for axitinib treatment was 10.9 months ( 95% CI 5.8- 13.5), and the median overall survival ( OS) from the start of axitinib treatment was 39.8 months ( 95% CI 25.9- NR), respectively. The PFS ( P < 0.0001) and OS ( P = 0.0022) were significantly correlated with the International mRCC Database Consortium ( IMDC) classification, respectively. The PFS and OS were significantly longer in patients who received longer prior treatment ( P = 0.0424 and 0.0067, respectively). On- treatment hypertension, hand foot syndrome and hypothyroidism were associated with longer PFS ( P = 0.0002, 0.0055 and 0.0290, respectively). Ontreatment hypertension, diarrhea, and hand foot syndrome were associated with longer OS ( P = 0.0004, 0.0036 and 0.0115, respectively). Conclusions: Baseline and on treatment factors are identified as prognostic markers in mRCC patients treated with axitinib. Our findings might be helpful for clinicians to select the best treatment to individual patients.

引用

页码：1170 / 1174

页数：5

共 15 条

[1] Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma [J].

Bono, P. ;

Elfving, H. ;

Utriainen, T. ;

Osterlund, P. ;

Saarto, T. ;

Alanko, T. ;

Joensuu, H. .

ANNALS OF ONCOLOGY, 2009, 20 (02) :393-394

[2] Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Escudier, B. ;

Powles, T. ;

Mainwaring, P. N. ;

Rini, B. I. ;

Donskov, F. ;

Hammers, H. ;

Hutson, T. E. ;

Lee, J-L ;

Peltola, K. ;

Roth, B. J. ;

Bjarnason, G. A. ;

Geczi, L. ;

Keam, B. ;

Maroto, P. ;

Heng, D. Y. C. ;

Schmidinger, M. ;

Kantoff, P. W. ;

Borgman-Hagey, A. ;

Hessel, C. ;

Scheffold, C. ;

Schwab, G. M. ;

Tannir, N. M. ;

Motzer, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (19) :1814-1823

[3] Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups [J].

de Velasco, Guillermo ;

Miao, Diana ;

Voss, Martin H. ;

Hakimi, A. Ari ;

Hsieh, James J. ;

Tannir, Nizar M. ;

Tamboli, Pheroze ;

Appleman, Leonard J. ;

Rathmell, W. Kimryn ;

Van Allen, Eliezer M. ;

Choueiri, Toni K. .

CANCER IMMUNOLOGY RESEARCH, 2016, 4 (10) :820-822

[4] Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients [J].

Donskov, Frede ;

Michaelson, M. Dror ;

Puzanov, Igor ;

Davis, Mellar P. ;

Bjarnason, Georg A. ;

Motzer, Robert J. ;

Goldstein, David ;

Lin, Xun ;

Cohen, Darrel P. ;

Wiltshire, Robin ;

Rini, Brian I. .

BRITISH JOURNAL OF CANCER, 2015, 113 (11) :1571-1580

[5] CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma [J].

Escudier, Bernard ;

Sharma, Padmanee ;

McDermott, David F. ;

George, Saby ;

Hammers, Hans J. ;

Srinivas, Sandhya ;

Tykodi, Scott S. ;

Sosman, Jeffrey A. ;

Procopio, Giuseppe ;

Plimack, Elizabeth R. ;

Castellano, Daniel ;

Gurney, Howard ;

Donskov, Frede ;

Peltola, Katriina ;

Wagstaff, John ;

Gauler, Thomas C. ;

Ueda, Takeshi ;

Zhao, Huanyu ;

Waxman, Ian M. ;

Motzer, Robert J. .

EUROPEAN UROLOGY, 2017, 72 (06) :962-971

[6] Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study [J].

Heng, Daniel Y. C. ;

Xie, Wanling ;

Regan, Meredith M. ;

Warren, Mark A. ;

Golshayan, Ali Reza ;

Sahi, Chakshu ;

Eigl, Bernhard J. ;

Ruether, J. Dean ;

Cheng, Tina ;

North, Scott ;

Venner, Peter ;

Knox, Jennifer J. ;

Chi, Kim N. ;

Kollmannsberger, Christian ;

McDermott, David F. ;

Oh, William K. ;

Atkins, Michael B. ;

Bukowski, Ronald M. ;

Rini, Brian I. ;

Choueiri, Toni K. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5794-5799

[7] Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma [J].

Hudes, Gary ;

Carducci, Michael ;

Tomczak, Piotr ;

Dutcher, Janice ;

Figlin, Robert ;

Kapoor, Anil ;

Staroslawska, Elzbieta ;

Sosman, Jeffrey ;

McDermott, David ;

Bodrogi, Istvan ;

Kovacevic, Zoran ;

Lesovoy, Vladimir ;

Schmidt-Wolf, Ingo G. H. ;

Barbarash, Olga ;

Gokmen, Erhan ;

O'Toole, Timothy ;

Lustgarten, Stephanie ;

Moore, Laurence ;

Motzer, Robert J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) :2271-2281

[8] Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma [J].

Motzer, R. J. ;

Escudier, B. ;

McDermott, D. F. ;

George, S. ;

Hammers, H. J. ;

Srinivas, S. ;

Tykodi, S. S. ;

Sosman, J. A. ;

Procopio, G. ;

Plimack, E. R. ;

Castellano, D. ;

Choueiri, T. K. ;

Gurney, H. ;

Donskov, F. ;

Bono, P. ;

Wagstaff, J. ;

Gauler, T. C. ;

Ueda, T. ;

Tomita, Y. ;

Schutz, F. A. ;

Kollmannsberger, C. ;

Larkin, J. ;

Ravaud, A. ;

Simon, J. S. ;

Xu, L-A ;

Waxman, I. M. ;

Sharma, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (19) :1803-1813

[9] Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer [J].

Ravaud, A. ;

Sire, M. .

ANNALS OF ONCOLOGY, 2009, 20 (05) :966-967

[10] Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial [J].

Rini, Brian I. ;

Melichar, Bohuslav ;

Ueda, Takeshi ;

Gruenwald, Viktor ;

Fishman, Mayer N. ;

Arranz, Jose A. ;

Bair, Angel H. ;

Pithavala, Yazdi K. ;

Andrews, Glen I. ;

Pavlov, Dmitri ;

Kim, Sinil ;

Jonasch, Eric .

LANCET ONCOLOGY, 2013, 14 (12) :1233-1242

← 1 2 →